UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 247,332 Shares of Standard BioTools Inc. (NASDAQ:LAB)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 80.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 554,203 shares of the company's stock after purchasing an additional 247,332 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.15% of Standard BioTools worth $970,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Takeda Pharmaceutical Co. Ltd. acquired a new position in Standard BioTools during the fourth quarter valued at approximately $29,000. Two Sigma Securities LLC bought a new position in shares of Standard BioTools during the fourth quarter worth $30,000. Aquatic Capital Management LLC acquired a new position in shares of Standard BioTools in the 4th quarter valued at $45,000. Cibc World Markets Corp acquired a new position in shares of Standard BioTools in the 4th quarter valued at $48,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Standard BioTools in the 4th quarter valued at $70,000. 53.74% of the stock is currently owned by institutional investors.

Standard BioTools Trading Down 0.5%

Shares of NASDAQ:LAB traded down $0.01 during trading on Thursday, hitting $1.08. 116,029 shares of the company's stock traded hands, compared to its average volume of 2,089,323. Standard BioTools Inc. has a 52 week low of $0.92 and a 52 week high of $2.45. The company has a market cap of $408.31 million, a price-to-earnings ratio of -1.51 and a beta of 1.50. The company has a 50-day moving average price of $1.10 and a 200-day moving average price of $1.39.

Analysts Set New Price Targets

Separately, KeyCorp lowered Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday, February 27th.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.